Mechanisms of action of bisphosphonates

Revue du Rhumatisme (English Edition)

Volumn 66, Issue 6, 1999, Pages 339-343

  Breuil, V ^a  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

Bisphosphonates

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; PAMIDRONIC ACID;

BONE MASS; BONE METABOLISM; BONE METASTASIS; BONE STRENGTH; BONE TURNOVER; HUMAN; HYPERCALCEMIA; MULTIPLE MYELOMA; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; REVIEW;

ANIMALS; BONE AND BONES; BONE RESORPTION; DIPHOSPHONATES; HUMANS; SENSITIVITY AND SPECIFICITY;

EID: 0033304218     PISSN: 11698446     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Bisphosphonates in the treatment of osteoporosis in 1997: A review
2. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events
3. Effects of disodium dichloromethylene diphosphonate on Paget's disease of bone
4. Effect of dichloromethylene diphosphonate on Paget's disease of bone and hypercalcaemia due to hyperparathyroidism or malignant disease
5. The binding of pyrophosphate and two diphosphonates on hydroxyapatite crystals
6. Retention of etidronate in human, dog and rat
7. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
8. Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis
9. The effects of risedronate on canine cancellous bone remodeling: Three-dimensional kinetic reconstruction of the remodeling site
10. Recurrence of vertebral fracture with cyclical etidronate therapy in osteoporosis: Histomorphometry and X-Ray microanalysis evaluation
11. The effects of 2-years treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strenght in ovariectomized nonhuman primates
12. Bone mineral density reflects bone mass but also the degree of mineralization of bone: Therapeutic implications
13. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture in vivo
14. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow
15. Protein-tyrosine phosphatase activity regulates osteoclast formation and function: Inhibition by alendronate
16. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts
17. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption
18. A possible mechanism of the specific action of bisphosphonates on osteoclasts: Tiludronate preferentially affects polarized osteoclasts having a ruffled border
19. Human osteoclast formation and activity in vitro: Effects of alendronate
20. Effect of alendronate treatment on the osteoclastogenesis of bone marrow cells in mice
21. Bisphosphonate action: Alendronate localization in rat bone and effects on osteoclast ultrastructure
22. Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemic models
23. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
24. Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism
25. The influence of 1-hydroxyethane-1,1-diphosphonate and dichloromethanediphosphonate on lysine hydroxylation and cross-link formation in rat bone, cartilage and skin collagen
26. Alendronate stimulates b-FGF production and mineralized nodule formation in human osteoblastic cells and osteoblastogenesis in human bone marrow cultures
27. Acid extrusion is induced by osteoclast attachment to bone: Inhibition by alendronate and calcitonin
28. +ATPase
29. Inhibitory effects of bisphosphonates on growth of amoebae of the cellular slime mold Dictostelium discodeum
30. Requirement of pp60(c-scr) expression for osteoclasts to form ruffled borders and resorb bone in mice
31. The when and how of src regulation
32. Lipophilic 1,1-bisphosphonates are potent squalene synthetase inhibitors and orally active cholesterol lowering agents in vivo
33. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras
34. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: Evidence from structure-activity relationships in J774 macrophages
35. Alendronate mechanism of action: Geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption and kinase activation in vitro
36. Protein synthesis is required for caspase activation and induction of apoptosis by bisphosphonate drugs
37. The role of protein geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates
38. Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis
39. Effects of clodronate (dichloromethylene bisphosphonate) on the development of experimental atherosclerosis in rabbits
40. Bisphosphonates cause apoptosis in human myeloma cells in vitro by inhibiting the mevalonate pathway
41. The bisphosphonate ibandronate increases apoptosis of metastatic breast cancer cells as well as osteoclasts
42. Bisphosphonate (alendronate) - Induced apoptosis in human lung adenocarcinoma cells is suppressed by geranygeranyl pyrophosphate
43. Bisphosphonates modulate interactions between breast cancer cells and osteoblasts
44. Bisphosphonates inhibit the platelet-aggregating activity of tumor cells, a process involved during hematogenous dissemination of metastatic cells
45. Bisphosphonates inhibit prostate and breast carcinoma cell invasion, but not tumor cell migration, through a mechanism independant of apoptosis induction